AAV Capsid Serotypes for CNS Cell Type Specificity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene therapy methods for the central nervous system (CNS) face challenges in optimizing the delivery of therapeutic agents, as they lack efficient targeting and temporal/spatial control of transgene expression, leading to suboptimal treatment outcomes for CNS disorders.
Innovation Solution
Development of adeno-associated virus (AAV) capsid serotypes with specific CNS cell type tropism, combined with optimized regulatory elements and codon optimization of the AAV genome, to create novel AAV particles that target specific cells and tissues within the CNS, enabling precise gene delivery and expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Area of stationary object
If AAV-based gene delivery is used to achieve widespread distribution of therapeutic genes in the CNS, then the coverage area is improved, but the specificity of targeting particular cell types is worsened
Solution Approach 1:
The patent applies local quality by using different AAV capsid serotypes with distinct tropism profiles to target specific cell types within the CNS. Each serotype is selected based on its ability to preferentially infect particular neuronal or glial populations, thereby achieving cell-type-specific gene delivery while maintaining widespread CNS distribution. This resolves the contradiction by making the delivery system's properties location- and cell-type-dependent rather than uniform.
2Manufacturing precision
If regulatory elements are optimized to control temporal and spatial expression of therapeutic transgenes, then the precision of gene expression is improved, but the complexity of the delivery system is worsened
Solution Approach 1:
The patent applies segmentation by dividing the gene expression control into separate functional modules: tissue-specific promoters for spatial control, inducible promoters for temporal control, and specific regulatory elements for cell-type control. Each module can be independently optimized and combined, allowing precise control of transgene expression while maintaining a modular, manageable delivery system structure.
3Manufacturing precision
If different AAV serotypes are used to target different CNS tissues and cell types, then the specificity of targeting is improved, but the difficulty of optimizing delivery parameters is worsened
Solution Approach 1:
The patent applies universality by developing a comprehensive library of AAV serotypes with characterized tropism profiles that can be selected based on target cell type. This universal approach allows the same basic delivery platform and therapeutic transgene to be used across different CNS targets by simply changing the capsid serotype, thereby maintaining ease of manufacturing while achieving high targeting specificity through serotype selection rather than complex parameter optimization.
Data Source
AI summary
The present disclosure relates to compositions, methods and processes for the formulation and for the administration of a gene therapy agent using parvovirus e.g., adeno-associated virus (AAV) to the CNS, CNS tissues, CNS structures or CNS cells.